Competing in the Post-Patent GLP-1 Market: Four Operational Risks
The Coming Wave of GLP-1 Competition The global success of GLP-1s has reshaped the metabolic disease landscape, driving unprecedented demand across diabetes, obesity, and adjacent indications. As key patents for leading products (such as semaglutide and tirzepatide) approach expiration in various countries, a new wave of companies, ranging from traditional generics manufacturers to complex peptide […]
